Cervical Cancer

Independent Studies Confirm Performance of Screening Products

Published in Cancer Weekly, April 11th, 2000

TriPath Imaging, Inc., Burlington, North Carolina, announced that six scientific studies have confirmed the successful use of both the AutoCyte PREP System (PREP) and the AutoPap Primary Screening System (AutoPap).

The results of the studies were presented at the recent International Academy of Cytology (IAC) Conference in Chicago, Illinois.

Three studies demonstrated the performance of the AutoCyte PREP. The first PREP study, an independent study by Dr. A. Verhest and colleagues, entitled "Comparison of the AutoCyte PREP with the Conventional Pap Smear in Cervical Cancer Screening," found that, "the routine use of cell suspension with the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2000-04-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry